AU Patent

AU2021236570B2 — Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof

Assigned to AbbVie Inc · Expires 2023-11-02 · 3y expired

What this patent protects

PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4 (3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2 TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF ABSTRACT The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,…

USPTO Abstract

PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4 (3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2 TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF ABSTRACT The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2 a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by process.

Drugs covered by this patent

Patent Metadata

Patent number
AU2021236570B2
Jurisdiction
AU
Classification
—
Expires
2023-11-02
Drug substance claim
No
Drug product claim
No
Assignee
AbbVie Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.